-DOCSTART- -X- O
Targeted -X- _ O
therapy -X- _ O
is -X- _ O
currently -X- _ O
limited -X- _ O
for -X- _ O
patients -X- _ O
with -X- _ O
hepatocellular -X- _ B-Patient
carcinoma -X- _ I-Patient
( -X- _ I-Patient
HCC -X- _ I-Patient
) -X- _ I-Patient
due -X- _ O
to -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
suitable -X- _ O
targets. -X- _ O
Kinases -X- _ O
play -X- _ O
pivotal -X- _ O
roles -X- _ O
in -X- _ O
many -X- _ O
cellular -X- _ O
biological -X- _ O
processes -X- _ O
, -X- _ O
whereas -X- _ O
dysregulation -X- _ O
of -X- _ O
kinases -X- _ O
may -X- _ O
lead -X- _ O
to -X- _ O
various -X- _ O
diseases -X- _ O
, -X- _ O
particularly -X- _ O
cancer. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
role -X- _ O
of -X- _ O
kinases -X- _ O
in -X- _ O
HCC -X- _ O
malignancy -X- _ O
remains -X- _ O
unclear. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
employed -X- _ O
a -X- _ O
kinome -X- _ O
small -X- _ O
interfering -X- _ O
RNA -X- _ O
( -X- _ O
siRNA -X- _ O
) -X- _ O
library -X- _ O
, -X- _ O
comprising -X- _ O
710 -X- _ O
kinase-related -X- _ B-Intervention
genes -X- _ I-Intervention
, -X- _ O
to -X- _ O
screen -X- _ O
whether -X- _ O
any -X- _ O
kinases -X- _ O
were -X- _ O
essential -X- _ O
for -X- _ O
cell -X- _ O
proliferation -X- _ O
in -X- _ O
various -X- _ B-Patient
HCC -X- _ I-Patient
cell -X- _ I-Patient
lines. -X- _ I-Patient
Through -X- _ O
a -X- _ O
kinome -X- _ O
siRNA -X- _ O
library -X- _ O
screening -X- _ O
, -X- _ O
we -X- _ O
found -X- _ O
that -X- _ O
MAP3K7 -X- _ B-Outcome
was -X- _ I-Outcome
a -X- _ I-Outcome
crucial -X- _ I-Outcome
gene -X- _ I-Outcome
for -X- _ I-Outcome
HCC -X- _ I-Outcome
cell -X- _ I-Outcome
proliferation. -X- _ I-Outcome
Pharmacological -X- _ I-Outcome
or -X- _ I-Outcome
genetic -X- _ I-Outcome
ablation -X- _ I-Outcome
of -X- _ I-Outcome
MAP3K7 -X- _ I-Outcome
diminished -X- _ I-Outcome
the -X- _ I-Outcome
growth -X- _ I-Outcome
, -X- _ I-Outcome
migration -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
invasion -X- _ I-Outcome
of -X- _ I-Outcome
HCC -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
primary -X- _ I-Outcome
HCC -X- _ I-Outcome
cells. -X- _ I-Outcome
Stable -X- _ O
knockdown -X- _ O
of -X- _ O
MAP3K7 -X- _ B-Intervention
attenuated -X- _ O
tumor -X- _ O
formation -X- _ O
in -X- _ O
a -X- _ O
spheroid -X- _ O
cell -X- _ O
culture -X- _ O
model -X- _ O
and -X- _ O
tumor -X- _ O
xenograft -X- _ O
mouse -X- _ O
model. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
silencing -X- _ B-Outcome
MAP3K7 -X- _ I-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
phosphorylation -X- _ I-Outcome
and -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
mammalian -X- _ I-Outcome
target -X- _ I-Outcome
of -X- _ I-Outcome
rapamycin -X- _ I-Outcome
( -X- _ I-Outcome
mTOR -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
HCC -X- _ I-Outcome
cells. -X- _ I-Outcome
MAP3K7 -X- _ I-Outcome
expression -X- _ I-Outcome
was -X- _ I-Outcome
positively -X- _ I-Outcome
correlated -X- _ I-Outcome
with -X- _ I-Outcome
mTOR -X- _ I-Outcome
expression -X- _ I-Outcome
in -X- _ I-Outcome
tumors -X- _ I-Outcome
of -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
HCC. -X- _ I-Outcome
Higher -X- _ I-Outcome
co-expression -X- _ I-Outcome
of -X- _ I-Outcome
MAP3K7 -X- _ I-Outcome
and -X- _ I-Outcome
mTOR -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
poor -X- _ I-Outcome
prognosis -X- _ I-Outcome
of -X- _ I-Outcome
HCC. -X- _ I-Outcome
Taken -X- _ I-Outcome
together -X- _ I-Outcome
, -X- _ I-Outcome
our -X- _ I-Outcome
results -X- _ I-Outcome
revealed -X- _ I-Outcome
that -X- _ I-Outcome
the -X- _ I-Outcome
MAP3K7-mTOR -X- _ I-Outcome
axis -X- _ I-Outcome
might -X- _ I-Outcome
promote -X- _ I-Outcome
tumorigenesis -X- _ I-Outcome
and -X- _ I-Outcome
malignancy -X- _ I-Outcome
, -X- _ O
which -X- _ O
provides -X- _ O
a -X- _ O
potential -X- _ O
marker -X- _ O
or -X- _ O
therapeutic -X- _ O
target -X- _ O
for -X- _ O
HCC -X- _ O
patients -X- _ O
. -X- _ O

